Year: 2019

MONTREAL, Nov. 18, 2019 (GLOBE NEWSWIRE) — Osisko Metals Incorporated (the “Company” or “Osisko Metals”) (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce that drilling will begin to targeting sixty (60) initial prismatic-style targets have been chosen based on processing and analyses of the 2019 airborne gravity gradiometry (“AGG”) survey data in conjunction with LiDAR features and newly-interpreted structural controls on mineralization.These targets are specifically identified on criteria that are indicative of prismatic mineralization based on responses over known, in-situ, high grade prismatic deposits as measured by ground-based gravity surveys used as a control for the AGG system. The targets are distributed both within, and between, mineralized trends with many occurring in very sparsely drilled areas within...

Company Announcement No. 803On 11 November 2019, we initiated a share buyback programme, as described in Company Announcement No. 800 of 1 November 2019. According to the programme, the company will in the period from 11 November 2019 to 6 February 2020 purchase own shares up to a maximum value of DKK 2,500,000,000 and no more than 6,000,000 shares, corresponding to 2.55% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.As at today, DSV Panalpina A/S holds a total of 4,673,501 shares of a nominal value of DKK 1 in DSV Panalpina A/S, corresponding to 1.99% of the total number of issued shares of...

See notification in attachment. Attachment20191118 – Skeljungur – Júpíter rekstrarfélag hf. – Major shareholder announcement

Sjá flöggunartilkynningu í viðhengi. Viðhengi20191118 – Skeljungur – Júpíter rekstrarfélag hf. – flöggun

BOSTON, Nov. 18, 2019 (GLOBE NEWSWIRE) — Eagle Growth and Income Opportunities Fund (the “Fund”) (NYSE: EGIF) today announced the declaration of its monthly distribution for December 2019, as well as additional actions relating to the Fund’s operations that are intended to benefit Fund shareholders, including a share repurchase program and a proposal, if approved by the Fund’s shareholders, to shorten the Fund’s remaining term by three years.Fund Declares December 2019 DistributionThe Fund announced the declaration of its monthly distribution of $0.08 per common share, payable on December 31, 2019.  Based on the Fund’s share price of $15.60 as of its close on November 15, 2019, the distribution represents an annualized yield of 6.15%.  Information regarding the distribution rate is included for informational purposes...

TORONTO, Nov. 18, 2019 (GLOBE NEWSWIRE) — Terrace Global Inc. (“Terrace Global” or the “Company”) (TSXV:TRCE) is pleased to announce its participation in Cannabis Invest UK, taking place on November 18, 2019 in London, England.  Cannabis Invest UK is an exclusive event bringing together the world’s leading cannabis companies with Europe’s institutional and high net worth investors, and cannabis industry stakeholders. The event is taking place at the Langham Hotel and will provide attendees the opportunity to meet with top tier emerging cannabis companies totaling over $5 billion of market capitalization, and learn about key issues and trends in this transformational industry. Francisco Ortiz von Bismarck, Co-Founder and CEO, will present at the conference, and will be available for scheduled one-on-one meetings.Conference details...

Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumorsShares preclinical data for new, CD112R targeted antibody candidate, SRF813, and its ability to promote NK/T cell activationCAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to support the initiation of a phase 1/1b clinical study of SRF617 (targeting CD39). At an inaugural R&D day today, the Company will share progress across its portfolio including clinical development plans for SRF617 and SRF388 (IL-27), and preclinical data...

GAITHERSBURG, Md., Nov. 18, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in New York City. This event is designed for sellside research analysts and institutional investors and requires registration for onsite participants, as space is limited.To register for onsite participation at the event or for more information, please contact Robert Burrows, IRO for Emergent BioSolutions at burrowsr@ebsi.com or (240) 631-3280.Event AgendaEmergent’s senior management will provide a detailed overview of the company’s 2020-2024 Growth Strategy. Presenters include President and CEO, Robert G. Kramer; EVP, Business Operations, Adam Havey; EVP, Corporate Development and General Counsel, Atul Saran; EVP and CFO, Richard Lindahl; EVP,...

Í 46. viku 2019 keypti Reitir fasteignafélag hf. 1.800.000 eigin hluti fyrir 131.205.000 kr. eins og hér segir:Er hér um að ræða kaup félagsins á eigin hlutum í samræmi við endurkaupaáætlun félagsins sem var hrint í framkvæmd 2. september 2019, sbr. tilkynningu til Kauphallar þann 1. september 2019.